Navigation Links
Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
Date:4/28/2008

l chemistry, diverse & focused screening libraries, global logistics and wide range of biology services for pre-clinical discovery & development projects. http://www.chemdiv.com

About Syndexa Pharmaceuticals Corporation:

Syndexa is engaged in the discovery and development of a new generation of small-molecule drugs that target the biological interface between inflammatory and metabolic pathways, and provide a novel mechanism for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and atherosclerosis. Syndexa's current programs include the development of inhibitors of obesity-induced Endoplasmic Reticulum (ER) stress and c-jun N-terminal kinase (JNK). Founded by leading scientists from Harvard and University of California, San Diego, the company is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Cambridge, MA. For additional information, please visit http://www.syndexa.com.


'/>"/>
SOURCE ChemDiv, Inc.; Syndexa Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. Keryx Biopharmaceuticals Receives Nasdaq Notification
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
7. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
8. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
9. MacroChem Acquires Virium Pharmaceuticals
10. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
11. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... Arlington, Massachusetts (PRWEB) October 22, 2014 ... recently announced the release of a new infographic, ... was to create a beautifully designed, easy to follow ... Ebola's transmission, areas of outbreak, symptoms and prevention. , ... have discovered that the 2014 Ebola outbreak represents not ...
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... Boston Scientific,Corporation (NYSE: BSX ) today announced ... Drug Administration (FDA) to market its second-generation,TAXUS(R) Liberte(R) ... the TAXUS Liberte stent early next month in ... its TAXUS(R),Expresss2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System, which ...
... Beike,Biotechnology Co. Ltd., ( http://www.beikebiotech.com ) ... through evidence-based medicine, announced,today it has signed eight ... the world,s most outstanding stem cell research organizations.,As ... a "Stem Cell Expert,Advisory Committee" and a separate ...
... WILMINGTON, Del., Oct. 10 AstraZeneca (NYSE:,AZN) today ... (FDA) has,approved once-daily SEROQUEL XR(R) (quetiapine fumarate) Extended-Release,Tablets ... associated with,bipolar disorder, the manic and mixed episodes ... of bipolar I disorder as adjunctive,therapy to lithium ...
Cached Biology Technology:Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 2Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent 3Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 3FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 2FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 3FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 4FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 5FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 6FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 7FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 8FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania 9
(Date:10/19/2014)... household electricity access in India over the last ... total carbon emissions growth during that time, according ... Nature Climate Change ., "Energy access is ... aspects of life, including education, communication, and health," ... study. , While increased energy access is widely ...
(Date:10/17/2014)... available in German . ... every day in order to reproduce? And why are there ... of the latest issue of the research journal Molecular ... biologist Steven Ramm from Bielefeld University Bielefeld has compiled this ... unusual for a female to copulate with several males in ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... today by the University of Victoria ranks eco-labels intended ... environment. It is the first study to evaluate how ... in the marketplace. "How Green is Your ... competing sustainability claims and better identify those labels that ...
... significantly advance our understanding of the genetic basis of ... past year. They are the users of a web-based ... McGill School of Computer Science and collaborator Mathieu Blanchette. ... contribute to scientific research by arranging multiple sequences of ...
... details of an anthrax bacteriophage a virus that infects ... infects its host, and providing an initial blueprint for how ... the detection and destruction of anthrax and other potential bioterror ... spore-binding phage 8a (or SBP8a, for short), is too small ...
Cached Biology News:New study puts eco-labels to the test 2Video game players advancing genetic research 2Researchers reveal SBP8a configurations 2Researchers reveal SBP8a configurations 3
CHIMAERIC HUMAN IgA2 ANTI NP...
... Zero Background/Kan Cloning Kit includes ... resistance for selection in E. ... positive selection to eliminate high ... of the reagents you need ...
RABBIT ANTI RAT AQUAPORIN 5...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Biology Products: